Picture of Adalta logo

1AD — Adalta News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Australia's AdAlta rises on FDA granting orphan drug status to lead cancer therapy

BUZZ-Australia's AdAlta rises on FDA granting orphan drug status to lead cancer therapy

** Shares of Australia's AdAlta 1AD.AX rise as much as 20% to A$0.003

** Stock set for its second consecutive session of gains if trend holds

** Biotech firm says US FDA Orphan Drug Designation for EW-001 in mesothelioma assigned

** EW-001 is a CAR-T cell therapy being developed to treat malignant mesothelioma, a rare and aggressive cancer often linked to asbestos exposure

** Near 3.8 million shares change hands, 1.0x the 30-day average volume

** Stock has fallen 16.7% YTD, including session moves


(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com;))

Recent news on Adalta

See all news